WO2003053222A3 - Methods for treating conditions, disorders, or diseases involving cell death - Google Patents

Methods for treating conditions, disorders, or diseases involving cell death Download PDF

Info

Publication number
WO2003053222A3
WO2003053222A3 PCT/US2002/040643 US0240643W WO03053222A3 WO 2003053222 A3 WO2003053222 A3 WO 2003053222A3 US 0240643 W US0240643 W US 0240643W WO 03053222 A3 WO03053222 A3 WO 03053222A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell death
methods
disorders
diseases involving
treating conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/040643
Other languages
French (fr)
Other versions
WO2003053222A2 (en
Inventor
Stuart D Portbury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cogent Neuroscience Inc
Original Assignee
Cogent Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cogent Neuroscience Inc filed Critical Cogent Neuroscience Inc
Priority to EP02795942A priority Critical patent/EP1467767A2/en
Priority to US10/495,323 priority patent/US20050107451A1/en
Priority to AU2002360665A priority patent/AU2002360665A1/en
Publication of WO2003053222A2 publication Critical patent/WO2003053222A2/en
Publication of WO2003053222A3 publication Critical patent/WO2003053222A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods for the treatment of conditions, disorders, or diseases involving cell death. The invention also relates to methods of preventing, inhibiting, or treating cells predisposed to undergo cell death or in the process of undergoing cell death. The invention further relates to methods of preventing, inhibiting, or treating cell death.
PCT/US2002/040643 2001-12-20 2002-12-20 Methods for treating conditions, disorders, or diseases involving cell death Ceased WO2003053222A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02795942A EP1467767A2 (en) 2001-12-20 2002-12-20 Methods for treating conditions,disorders,or diseases involving cell death
US10/495,323 US20050107451A1 (en) 2001-12-20 2002-12-20 Methods for treating conditions, disorders, or diseases involving cell death
AU2002360665A AU2002360665A1 (en) 2001-12-20 2002-12-20 Methods for treating conditions, disorders, or diseases involving cell death

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34271201P 2001-12-20 2001-12-20
US60/342,712 2001-12-20

Publications (2)

Publication Number Publication Date
WO2003053222A2 WO2003053222A2 (en) 2003-07-03
WO2003053222A3 true WO2003053222A3 (en) 2004-03-04

Family

ID=23342953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/040643 Ceased WO2003053222A2 (en) 2001-12-20 2002-12-20 Methods for treating conditions, disorders, or diseases involving cell death

Country Status (4)

Country Link
US (1) US20050107451A1 (en)
EP (1) EP1467767A2 (en)
AU (1) AU2002360665A1 (en)
WO (1) WO2003053222A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090876A1 (en) * 1991-07-03 1993-01-04 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
US5786173A (en) * 1996-03-19 1998-07-28 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use
US5858715A (en) * 1997-01-29 1999-01-12 Incyte Pharmaceuticals, Inc. Human apoptosis-associated protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents

Also Published As

Publication number Publication date
US20050107451A1 (en) 2005-05-19
AU2002360665A8 (en) 2003-07-09
EP1467767A2 (en) 2004-10-20
WO2003053222A2 (en) 2003-07-03
AU2002360665A1 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
MXPA03007920A (en) Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers.
WO2005030121A3 (en) Compounds, compositions and methods
WO2002028861A8 (en) Methods and compounds for treating proliferative diseases
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2001021771A3 (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
WO2004043379A3 (en) Chemical compounds
BR9906926A (en) Compositions and methods for treating cells having double minute dna
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2006021002A3 (en) Compounds useful for inhibiting chk1
TW200722090A (en) Compounds useful for inhibiting chk1
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
WO2001042784A3 (en) Methods for screening compounds active on neurons
CA2320717A1 (en) Method for the treatment of diseases or disorders of the inner ear
WO2003087411A8 (en) Method to inhibit cell growth using oligonucleotides
WO2001081361A8 (en) Compositions and method for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2003053222A3 (en) Methods for treating conditions, disorders, or diseases involving cell death
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
ZA200609220B (en) Method of treating dry eye disorders and uveitis
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
WO2005094840A8 (en) Compositions comprising mannose phosphate for vaginal treatment
WO2004076414A3 (en) Novel compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002795942

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002795942

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10495323

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002795942

Country of ref document: EP